Last updated: July 27, 2026
AstraZeneca LP v. Mylan Pharmaceuticals Inc. (1:15-cv-01000): Litigation Summary, Case Posture, and Patent-Exclusivity Impact
What is AstraZeneca LP v. Mylan Pharmaceuticals Inc. 1:15-cv-01000 about?
AstraZeneca LP brought a patent infringement action against Mylan Pharmaceuticals Inc. under the Hatch-Waxman framework (Paragraph IV context), docketed as 1:15-cv-01000. The case is a drug-patent enforcement matter tied to Mylan’s FDA generic development strategy for an AstraZeneca-branded product.
Which patents and Orange Book listings were litigated?
The record required to produce an accurate litigation summary must include at minimum:
- the asserted patent numbers (and claims)
- the Orange Book reference product and listed patents
- the FDA application number(s) and Paragraph IV notice details tied to the suit
No such case-specific litigation metadata (asserted patents, FDA NDA/ANDA identifiers, or Orange Book listings) is present in the information supplied here. Under operating constraints, a complete and accurate answer cannot be produced.
What court, jurisdiction, and procedural posture applies?
A complete summary requires verified procedural milestones for case 1:15-cv-01000, including:
- the court location (district and judge)
- complaint date and answer date
- claim construction schedule and rulings
- dispositive motions timeline (Rule 12/56)
- trial date status (if any)
- settlement or dismissal status (if resolved)
The provided input includes only the docket identifier, not the underlying docket facts. Without them, litigation posture and timing cannot be stated accurately.
When did the case progress, and what deadlines mattered for exclusivity?
A litigation impact analysis for a generic challenge depends on:
- filing date relative to FDA exclusivity windows (NCE exclusivity, 5-year/3-year exclusivity)
- whether a preliminary injunction was sought and ruled on
- whether a trial or Markman occurred
- the effective date of any settlement or dismissal
- any resulting “180-day exclusivity” triggers (first filer or later settlement chain)
Those dates are not provided. Under the constraints, no exclusivity-timeline analysis can be issued.
How does this litigation affect generic entry risk for Mylan and other ANDA filers?
To quantify entry risk, the analysis must know:
- whether an injunction issued
- whether the court entered a judgment of non-infringement or invalidity
- whether there was a covenant not to sue or licensing agreement
- which patents were adjudicated or dismissed without prejudice
- the status of the “trigger date” for 180-day exclusivity
None of those determinations or outcomes can be derived from the docket number alone. A risk analysis would require case-specific results.
What is the settlement and licensing status (if any), and what terms govern entry?
A settlement analysis requires:
- whether a settlement was reported
- the scope of a covenant not to sue
- launch-date commitments or design-around limitations
- authorized generic product labeling restrictions
- patent-by-patent carve-outs
- any license under AstraZeneca’s asserted patents
No settlement artifacts or terms are available in the supplied content.
How strong is AstraZeneca’s patent estate in the asserted technology area?
A credible “patent strength” view requires at least:
- the number of asserted patents
- remaining expiration dates
- whether patents are composition, formulation, method-of-use, or manufacturing
- prosecution history or claim construction outcomes
- the overlap with Orange Book listed patents for the relevant FDA reference product
Those inputs are not provided; an estates-strength conclusion would be unsupported.
How do patent expiration and exclusivity timelines shape the competitive landscape?
To link litigation to real-world launch timing, the answer must tie:
- asserted patent expiration dates
- any terminal disclaimers
- listed patent expiration in the Orange Book
- regulatory exclusivity (5-year NCE/brand exclusivity, pediatric exclusivity)
- any court-ordered effective launch dates from settlement
No such timeline data is provided.
What procedural events could have impacted appeal rights?
Appeal analysis needs:
- final judgment date
- whether appeals were taken
- whether PTAB proceedings or reexamination impacted the case
- whether a stay was entered pending appeal or PTO actions
No procedural record is included, so appeal analysis cannot be accurately written.
Case Impact Table (Required Inputs Not Provided)
| Litigation element |
Status needed for analysis |
Present in input |
Output |
| Asserted patent numbers and claims |
Yes |
No |
Cannot summarize |
| FDA application identifiers (NDA/ANDA) |
Yes |
No |
Cannot tie to Orange Book |
| Court, judge, district |
Yes |
No |
Cannot state posture |
| Key rulings (Markman, summary judgment, injunction) |
Yes |
No |
Cannot analyze outcomes |
| Settlement/dismissal terms |
Yes |
No |
Cannot assess launch timing |
| Patent expiration dates and exclusivity triggers |
Yes |
No |
Cannot model entry risk |
Key Takeaways
- A litigation summary and impact analysis for AstraZeneca LP v. Mylan Pharmaceuticals Inc., 1:15-cv-01000 requires docket-specific information (asserted patents, FDA application identifiers, procedural rulings, and outcome).
- The provided input contains only the case caption and docket number, which is insufficient to produce a complete and accurate litigation narrative under the stated constraints.
FAQs
- What asserted patents are listed in AstraZeneca LP v. Mylan Pharmaceuticals Inc. 1:15-cv-01000?
- Which FDA NDA/ANDA and Paragraph IV notice are linked to the suit?
- Did AstraZeneca obtain any preliminary injunction or stay of generic launch in 1:15-cv-01000?
- What was the final disposition of claims in the case, and was it appealed?
- How did the outcome of 1:15-cv-01000 affect the timing of generic market entry?
References
No sources were provided in the input.
